Related Experiment Videos
Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas
E Bajetta1, R Buzzoni, P Valagussa
1Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
American Journal of Clinical Oncology
|April 1, 1988
Summary
Mitoxantrone shows effectiveness in treating refractory non-Hodgkin's lymphomas (NHL). This phase II study found a 47% response rate with good tolerability, suggesting its use in salvage regimens.
Area of Science:
- Oncology
- Pharmacology
Background:
- Refractory non-Hodgkin's lymphomas (NHL) present a significant treatment challenge.
- Salvage chemotherapy regimens are crucial for patients with relapsed or refractory disease.
Purpose of the Study:
- To evaluate the efficacy and safety of mitoxantrone in patients with refractory NHL.
- To determine the response rate and tolerability of mitoxantrone as a salvage therapy.
Main Methods:
- A phase II study involving 31 patients with refractory NHL.
- Mitoxantrone administered intravenously at 14 mg/m2 every 3 weeks.
- Response assessed after a minimum of two cycles; cardiac function monitored via EKGs.
Main Results:
- A 47% overall response rate (14 of 30 evaluable patients), including 9 complete responses (CR) and 5 partial responses (PR).
- In patients previously treated with Adriamycin, 5 achieved CR and 2 achieved PR.
- Mitoxantrone was well tolerated with mild leukopenia and thrombocytopenia; no major cardiac abnormalities were detected.
Conclusions:
- Mitoxantrone is an effective agent for patients with refractory NHL.
- The drug demonstrates a favorable safety profile, including cardiac safety.
- Mitoxantrone should be considered for inclusion in salvage regimens for refractory NHL.